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Case report
Failure to detect Borna disease virus infection in
peripheral blood leukocytes from humans with
psychiatric disorders
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The presence of antibodies reactive with Borna disease virus (BDV) in the sera
of some patients with certain psychiatric illnesses has been taken as evidence
that this veterinary neurotrophic virus may occasionally infect and cause
psychiatric disorders in humans. In this paper, we report the results of our
studies concerning the detection of BDV-specific RNA in blood cells from
patients with psychiatric diseases. Contrary to the results obtained by others,
we have found no evidence for the presence of BDV-RNA in such cells. Prior
workwithBDVsequencesintheassayenvironment,togetherwiththeexquisite
sensitivity of RT-PCR, may account for the sporadic appearance of false
positive evidence that BDV-specific RNA is present in human blood cells.
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Introduction
Borna disease virus (BDV) has been promoted as a
contributor to psychiatric disease in humans. The
first reports on the presence of BDV-reactive
antibodies in the sera of patients with mood
disorders were followed by other serological data
showing that BDV-reactive antibodies are present in
the sera of a significantly greater proportion of
mentally ill patients than normal individuals
(Amsterdam et al, 1985; Rott et al, 1985, 1991;
Bode et al, 1988; VandeWoude et al, 1990; Bechter
et al, 1992; Fu et al, 1993; Waltrip et al, 1995). This
led to the hypothesis that human BDV infection
may contribute to the pathogenesis of certain
human psychiatric disorders. Using the RT-PCR
technique, several investigators have reported the
detection of BDV-specific RNA sequences in per-
ipheral blood leucocytes (PBL) obtained from
psychiatric patients (Bode et al, 1995; Kishi et al,
1995a,b). To further investigate these observations
as well as provide preliminary evidence concerning
the geographical distribution of psychiatric patients
with PBL-borne BDV-sequences, we have con-
ducted a multicenter study in Germany, where
Borna disease (BD) is indigenous (Rott and Becht,
1995), and the US, where BD is unknown (Kao et al,
1993), to examine, using molecular approaches
under rigidly controlled conditions, the prevalence
of BDV-sequences in human PBL.
Results
RT-PCR
In the work performed in Philadelphia, 10 schizo-
phreinc patients and 10 age and sex matched
control individuals from the area were studied.
Sera from two of the schizophrenic patients had
high titers (1:540; 1:4860) of BDV-reactive anti-
bodies as determinedby Westernblot analysis using
BDV-antigens prepared from a homogenate of BDV-
infected rat brain. One of these patients was bled
four times over a 3 month period and showed a
consistently high BDV-reactive antibody titer. The
RT-PCR assay was conducted using primers specific
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1997 Journal of NeuroVirology, Inc.for the p38 BDV-gene. Two samples gave positive
RT-PCR results in only the laboratory currently
engaged in BDV work. In the other two laboratories
not previously exposed to BDV, the outcome of RT-
PCR analysis of replicates of these samples was
negative (Table 1). In no other sample was a positive
reaction yielding BDV-specific sequences obtained
(Table 1).
In Giessen, PBLs from 42 seropositive psychiatric
patients and four seronegative controls from a BDV
endemic area in Germany (Gu Ènzburg) were again
analyzed in the two classes of laboratories. In this
case, the more sensitive nested PCR method was
used with primers specific for the BDV p24-gene.
Positive results with PBLs from two patients were
again obtained in only the laboratory where BDV
work was ongoing, but not confirmed in another
independent BDV-free laboratory (Table 1). All the
other samples were negative (Table 1). In addition,
consecutive samples obtained from these indivi-
duals over a 9 month period were studied and in no
case were BDV-sequences detected (Table 2). We
found that the seropositive patients remained
positive for BDV-specific antibodies and the ser-
onegative controls did not seroconvert (data not
shown).
Infectivity
In attempts to recover virus from PBLs of seroposi-
tive patients, we either cocultivated these with
rabbit embryonic brain (REB) cells or injected them
into rabbits, i.c., since rabbits and REB cells are
highly susceptible to BDV infection (Ludwig et al,
1988). Immunofluorescence analysis was used to
survey REB cells for evidence of BDV infection and
immunoblot techniques used in an effort to detect
BDV-antigens in extracts of the cells. Cocultivation
of REB cells with PBLs from the Giessen cohort of
seropositive patients through either two (47 PBL
samples) or 8±10 (eight PBL samples) passages
failed to provide any evidence of the presence of
BDV.
Furthermore, i.c. inoculation of two rabbits with
PBLs prepared from the Philadelphia patient
exhibiting the highest anti-BDV titer neither caused
clinical disease nor the induction of BDV-specific
antibodies in the animals during a 2 month
observation period.
Discussion
A possible association between BDV-infection and
major psychiatric disorders was initially proposed
on the basis of finding BDV-reactive antibodies in
the sera of relatively minor subsets of such patients
(Amsterdam et al, 1985; Rott et al, 1985, 1991;
Bode et al, 1988; VandeWound et al, 1990; Bechter
et al, 1992; Fu et al, 1993; Waltrip et al, 1995). The
more recent detection of BDV antigens, and BDV-
RNA by RT-PCR, in PBLs of psychiatric patients
(Bode et al, 1995; Kishi et al, 1995a,b) has been
taken as evidence of the presence of BDV antigens
and, presumably, BDV itself, in these individuals.
Surprisingly however, there has been no correla-
tion found between the presence of BDV RNA or
BDV antigens and seropositivity to BDV antigens in
individual patients. Moreover, only a few patients
have been identified whose serum antibodies have
reacted with both the p-38 and p-24 antigens of
BDV whereas sera of naturally infected horses
(unpublished observations) and experimentally
infected rats (Rott et al, 1991; Fu et al, 1993)
regularly exhibit antibodies to both antigens. These
observations prompted us to further evaluate
possible correlations between BDV and human
psychiatric illness. Two centers, one in Germany
and one in the USA, were involved in this study
and aliquots of the human material to be assayed
for BDV-RNA were tested independently in both
countries in at least two different classes of
laboratories; one being routinely engaged in BDV
Table 1 Analysis of human PBLs using RT-PCR with BDV-
specific primers
Presence of BDV-specific sequences/Number of individuals tested
(a) Philadelphia Schizophrenic Normal
cohort
1 patients controls
Lab 1
Lab 2
Lab 2
2/10
0/10
0/10
0/10
0/10
0/10
(b) Giessen cohort
2 Psychiatric patients Normal controls
Lab 1
Lab 2
2/24
0/24
0/4
n.d.
1Primers specific for the p38 BDV gene were used
2Primers specific for the p24 BDV gene were used; all
psychiatric patients were seropositive for BDV-specific anti-
bodies
Table 2 RT-PCR analysis of PBLs obtained in consecutive
bleeds of BDV seropositive and seronegative individuals
Number of subjects
1
positives
2 Number of bleeds Number of RT-PCR
(a) seropositive subjects:
32
6
2
1
1
1
2
3
4
5
0/32
0/12
0/6
0/4
0/5
(b) seronegative subjects:
4 2 0/8
1Subjects were selected as described in Materials and methods.
The psychiatric diagnoses of these individuals are detailed in
Table 1
2Primers specific for the p24 BDV gene were used
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to BDV.
We obtained positive results for the presence of
BDV-RNA only in laboratories where BDV is
routinely studied. Simultaneous or subsequent
analysis of replicate samples in other laboratories
where there had been no prior work on BDV yielded
negative results. In order to rule out the possibility
that BDV-specific RNA may appear only transiently
in patient's PBL, we obtained samples from the
peripheral blood of BDV-reactive, antibody seropo-
sitive, psychiatric patients at regular intervals. Even
in these serial consecutive bleedings, we failed to
detect BDV-sequences. In addition, we could not
detect BDV-infectivity in PBLs after as many as 10
serial passages of cocultivation with REB cells. We
are therefore forced to conclude that contamination
may seriously influence the outcome of studies
using RT-PCR methodology to probe for BDV-
sequences in PBLs of psychiatric patients, and
stringent criteria must be met to control against
false negative results. Henceforth, based on the data
currently available in the literature, we cannot
support the contention that BDV-specific sequences
are present in up to 30% of patients with psychiatric
illness.
The observation of psychiatric patients in the
Giessen and Philadelphia cohorts with serum
antibodies reactive with the p-24 and/or p38 BDV-
antigens but neither infectious virus nor BDV-
specific sequences detectable in their PBLs may
pose a question concerning the source of the
antigenic stimulus in humans. Is the antigen
responsible for the induction of antibodies in
humans actually BDV or some other infectious
agent, or a self component that cross-reacts with
BDV determinants?
One of the major considerations concerning the
use of RT-PCR to probe the putative link between
BDV-infection and human psychiatric disorders is
that the technique, as shown here, is susceptible to
`false' positive reactions, presumably due to its
exquisite sensitivity and contamination of the
laboratory with RNA. It should be noted that, in
our hands, the frequency of positive results
obtained in laboratories dedicted to work with
BDV, that we were unable to confirm in clean
laboratories, approaches that reported for sequence-
positive individuals in other studies (Bode et al,
1995; Kishi et al, 1995a,b).
Like other studies, our investigation suffers from
having examined only a small pool of psychiatric
patients and an even smaller number of controls.
Even though the presence of serum BDV-reactive
antibodies, itself a relatively infrequent occurrence,
was used to target individuals of interest, we were
unable to confirm the presence of BDV-specific
RNA sequences in PBLs from any of these. This does
not however exclude the possibility that BDV RNA
may be present in some psychiatric patients where
virus infection may be restricted to specialized
areas of the brain such as the limbic system which
are preferentially infected by BDV in naturally and
experimentally infected animals (Rott and Becht,
1995). We conclude that the tangible evidence
necessary to resolve the issue of whether or not
there is any direct association between BDV
infection and human psychiatric illness remains
elusive.
Materials and methods
US cohort
Subjects were randomly selected from the pool of
schizophrenic patients treated at the Thomas
Jefferson University Hospital (TJUH) in Philadel-
phia. Mean age of the seven male and three female
subjects was 38.0+13.3 S.D. years and the mean
duration of illness was 16.4+13.6 S.D. years.
Inclusion criteria for schizophenic subjects were
as follows: (1) DSM-4 diagnosis of schizophrenia or
schizoaffective disorder; (2) minimum 18 years of
age; (3) provision of informed consent. Exclusion
criteria for schizophrenic subjects were the pre-
sence of HIV-infection or other medical problems
likely to alter the presentation and/or treatment of
the psychiatric symptomology. A control group,
ethnically and age-matched to schizoprehic sub-
jects, was selected from the pool of volunteers
presenting at the TJUH blood donor center.
German cohort
The patients were from the University of Ulm,
Department of Psychiatry II, Berzirkskrankenhaus
Gu Ènsberg. BDV seropositive patients were ran-
domly selected from ongoing studies (positives
represented 42 out of a total pool of more than 500
seropositive tested individuals). The ICD-10 system
was utilized for psychiatric diagnosis (see Table 3).
The range of diagnoses obtained in the study group
covers the range found in seropositives from
Table 3 Diagnosis of Giessen/Gu Ènzburg Psychiatric Patients
General diagnosis
(# patients; total 42) ICD-10 diagnosis (# patients)
Schizophrenic disorders (16)
Depressive disorders (9)
Generalized anxiety disorders (4)
Personality disorders (3)
Organic personality disorders (3)
Alcoholic personality disorders (4)
Dementias (2)
Oligophrenia (1)
F20.xx±most paranoid type
in acute or post-acute stages
(10); first diseased (3),
chronic residua (3)
F32.1 (5)
F33.1 (4)
F41.1 (4)
F60.x (3)*
F07.x (3)*
F10.71 (4)
F0x.x (2)*
F71 (1)
*x and x.x indicates variable numbers (0±9) within the
respective codes
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psychiatric patients; however no selection was
made on the basis of diagnosis. Further inclusion/
exclusion criteria were as detailed for the Philadel-
phia cohort. Seronegative controls were volunteers
from the department's medical personnel.
Isolation of PBL
From each patient and control subjet, 10±20 ml of
blood was collected into heparinized (Philadelphia)
or EDTA-treated (Giessen) tubes. PBLs were pur-
ified, according to the manufacturer's protocol,
using Ficoll-Hypaque density gradient centrifuga-
tion (Pharmacia, Sweden). Blood was collected in
the hospital and PBLs were processed in labora-
tories which had no history of work with BDV or
BDV-specific nucleic acids. Replicate aliquots of
isolated PBLs were then distributed to the various
laboratories for further analysis.
RNA-extraction and RT-PCR reaction
RNA was isolated from PBLs using RNAzolB
(Biotecx, Texas). RT-PCR extractions were per-
formed in two classes of laboratories, one which
routinely carries out BDV investigations and an-
other which had no prior contact with BDV. In the
studies performed in Philadelphia, 1 mg or 50% of
the RNA obtained from a PBL sample was subjected
to reverse transcription with Superscript RT (Gibco
BRL) using the following anti-sense p38-specific
primer (Zimmerman et al, 1994):
5'-CTTCTTACTCCAGTAAAACGC-3'
After 1 h the cDNA was amplified using 39 PCR
cycles employing the following primers:
sense primer:
5'-GTCACGGCGCGATATGTTTC-3'
anti-sense primer:
5'-ATTCTTTACCTGGGGACTCA-3'
Amplification of 3-GAPDH was used as an internal
control using the following primers:
RT 5'-AAGCAGTTGGRGGRGCAGG-3'
PCR sense
5'-AAGGTGAAGGTCGGAGTCAA-3'
anti-sense
5'-TTCTCCATGGTGGTGAAGAC-3'
RNA from BDV-infected rat brain was included in
all experiments as a positive control. All samples
were coded and analyzed in a blinded fashion.
In the Giessen and Marburg studies, 50% of the
isolated RNA was reverse transcribed for 1 h at 428C
using p24-specific sense and anti-sense primers in
order to amplify genomic and subgenomic BDV-
specific RNA (Richt et al, 1993). The cDNA was
amplified using 32 PCR cycles as described pre-
viously (Zimmerman et al,1 9 9 4 ) .T h er e s u l t i n g
amplification products were subjected to a second
32 cycle PCR amplification using a nested primer
set:
nested p24 sense primer:
5'-TCAGACCCAGACCAGCGAA-3'
nested p24 anti-sense primer:
5'-AGCTGGGGATAAATGCGCG-3'
The products of amplification were analyzed in
agarose gel with subsequent Southern blot hybridi-
zation using an internal oligonucleotide P24 BDV
probe (Richt et al, 1993), 3' end labeled with
digoxigenin-11-dd-UTP (Cat No. 1362376; Boehrin-
ger Mannheim, Germany). RNA from BDV-infected
rat brain was tested in parallel as a positive control.
In the Marburg laboratory, positive control BDV
RNA was only used a single time to ensure the
quality of the newly synthesized primers and the
reaction conditions and was not included in the
subsequent assays with test samples.
Since pure BDV RNA is not available, the
sensitivity of the RT-PCR techniques employed
was tested using total RNA isolated from BDV-
infected rat brain containing 10
7 tissue culture
infectious doses of BDV per gm of tissue. Viral
RNA could be detected in as little as 0.2 picograms
of total rat brain RNA.
Experimental animals
In an attempt to recover BDV from potentially
infected human PBL, New Zealand white rabbits
were inoculated i.c. with approximately 10
6 PBL (in
50 ml medium) from a donor seropositive for BDV-
reactive antibodies. The rabbits were monitored
daily for 60 days for the appearance of clinical signs
of Borna disease and bled 40 and 60 days post
inoculation.
In vitro infectivity assays
In vitro infectivity assays were performed using
viable PBLs cocultivated with rabbit embryonic
brain (REB) cells (1:1 ratio). The cells were
passaged up to 10 times and then fixed in acetone
prior to being analyzed with BDV-convalescent rat
serum using the indirect immunofluorescence assay
described previously (Rott et al, 1991).
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